Esperion Therapeutics, Inc. (ESPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.180.00%
Close 2026-07-13 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Improve operating income from -$6.6M in 2026-Q1: metric not reported.
Esperion is merging with Essence Parent Inc. This merger could boost growth. Revenue is expected near $225 million in 2026. The company aims to improve its operating income from recent losses.
Esperion is still losing money and operating income is volatile. Revenue growth may slow below 6%. The merger may not improve profits soon.
The price is about 50% below our fair value near $6. Analysts expect about 6% revenue growth. Our view is more optimistic on growth and merger success.
Breaks if: merger not completed by end 2026
Finalize the merger agreement and transition to become a wholly owned subsidiary of Essence Parent Inc.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is navigating through a volatile management phase while trying to stabilize its financial performance after a recent merger.
The current valuation suggests that the market sees ESPR as relatively cheap compared to its peers. However, there is a notable expectations gap, indicating that investors may be cautious about the company's ability to deliver consistent results.
Fundamentally, ESPR is facing challenges with operating income, which has not shown sustainable improvement. The company has a high probability of missing earnings expectations, which adds to the uncertainty in the near term.
The future performance of ESPR hinges on management's ability to execute its priorities, particularly in improving operating income. Additionally, broader sector trends and the performance of key industry players will significantly influence ESPR's trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. The merger agreement was announced in 2026-Q2 and completed by 2026-Q2, resulting in the Company becoming a wholly owned subsidiary of Essence Parent Inc. The trajectory shows successful completion of this strategic priority.
“On May 1, 2026, Esperion entered into an Agreement and Plan of Merger with Essence Parent Inc.”
“On June 9, 2026, the Company announced the merger agreement with Essence Parent Inc.”
“On July 13, 2026, the merger was completed and the Company became a wholly owned subsidiary.”
Breaks if: operating income remains negative or worsens over FY26
Focus on achieving sustainable profitability and improving operating income over recent quarters.
Stated as a priority in 4 of last 4 quarters. Operating income improved from -$22.1M in 2025-Q1 to $85.2M in 2025-Q4 but then declined to -$6.6M in 2026-Q1. Management's expectation of sustainable profitability starting 2026-Q1 has not been met, indicating limited progress on this priority.
“Esperion expects to achieve sustainable profitability beginning in the first quarter of 2026.”
“The Company expects full year 2026 operating expenses to be in the range of $225 million to $255 million.”
“Esperion introduces its expectations for full-year 2026 operating expenses to be in the range of $210 million to $245 million.”
“The Company reiterates its expectation for full year 2025 operating expenses to be in the range of $215 million to $235 million.”
Breaks if: revenue falls below $215 million in FY26
In the next 1 to 3 years, ESPR's outlook remains cautious due to its mixed management execution and external sector pressures. Not investment advice.